Vimarsana
Biggest News Aggregation in the World

Page 3 - Harvard Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Harvard Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Harvard Bioscience Today - Breaking & Trending Today

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings - Vimarsana News

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended...

Several Insiders Invested In Harvard Bioscience Flagging Positive News - Vimarsana News

Several Insiders Invested In Harvard Bioscience Flagging Positive News

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Source: yahoo.com
Global Organ Perfusion System Market Research Report 2024 - Vimarsana News

Global Organ Perfusion System Market Research Report 2024

Dublin, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The

Punch & Associates Investment Management Inc. Buys 60,385 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Vimarsana News

Punch & Associates Investment Management Inc. Buys 60,385 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Punch & Associates Investment Management Inc. increased its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) by 2.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,923,034 shares of the medical instruments supplier’s stock after buying an additional […]

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock Holdings Lifted by Punch & Associates Investment Management Inc. - Vimarsana News

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock Holdings Lifted by Punch & Associates Investment Management Inc.

Punch & Associates Investment Management Inc. increased its position in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,923,034 shares of the medical instruments supplier’s stock after acquiring an additional 60,385 […]

Source: wkrb13.com